ArticleScientific reports2018
Toxic effects of selected proprietary dry eye drops on Acanthamoeba.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Article
- Amoebicidal Effect of COVID Box Molecules againstPharmaceuticals (Basel, Switzerland) · 2024Article
- Amoebicidal effect of synthetic indoles againstAntimicrobial agents and chemotherapy · 2024Article
- Molecular detection and characterization of Acanthamoeba infection in dogs and its association with keratitis in Korea.Parasites, hosts and diseases · 2024Article
- Diagnosis ofDiagnostics (Basel, Switzerland) · 2023Review
- Statins Induce Actin Cytoskeleton Disassembly and an Apoptosis-Like Process inAntibiotics (Basel, Switzerland) · 2022Article
- The therapeutic potential of novel isobenzofuranones against Naegleria fowleri.International journal for parasitology. Drugs and drug resistance · 2021Article
- High oxygen concentrations inhibit Acanthamoeba spp.Parasitology research · 2021Article
- In vitro evaluation of commercial foam Belcils® on Acanthamoeba spp.International journal for parasitology. Drugs and drug resistance · 2020Article
- Laurinterol from Laurencia johnstonii eliminates Naegleria fowleri triggering PCD by inhibition of ATPases.Scientific reports · 2020Article
- Combined Amoebicidal Effect of Atorvastatin and Commercial Eye Drops againstPathogens (Basel, Switzerland) · 2020Article
- Staurosporine from Streptomyces sanyensis activates Programmed Cell Death in Acanthamoeba via the mitochondrial pathway and presents low in vitro cytotoxicity levels in a macrophage cell line.Scientific reports · 2019Article
- Article
- Drug targeting in Acanthamoeba keratitis: rational of using drugs that are already approved for ocular use in non-keratitis indications.Eye (London, England) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amoebae of the genus Acanthamoeba are ubiquitous protists that have been isolated from many sources such as soils, water and the air. They are responsible for infections including fatal encephalitis and a severe keratitis in humans. To date, there is no satisfactorily effective therapeutic agent against this pathogen and the infections it causes are exacerbated by the existence of a resistant cyst stage produced by this amoeba. As dry eye syndrome is a risk factor for Acanthamoeba keratitis, we aimed to evaluate the anti-Acanthamoeba activity of a variety of proprietary eye drops intended to treat dry eye syndrome. From the nine eye drop formulations tested, "Systane Ultra" was determined to be the most active against all tested Acanthamoeba strains. During our investigations into the mode of action of Systane Ultra, we discovered that it decreases mitochondrial membrane potential and ATP levels, induces chromatin condensation, and increases the permeability of the plasma-membrane.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.